Biagio Ricciuti: Resistance mechanisms in insertion-mutant NSCLC

Biagio Ricciuti shared on X:

“Resistance mechanisms to EGFR TKIs in EGFR ex 20 insertion-mutant NSCLC:

• 9 patients treated with mobocertinib
  
• EGFR amp (focal or broad N=6)
  
• EGFR mutations (N=3, including C797S)
  
• aneuploidy (WGD and chr 7p gain).“

‘Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer‘

Authors: Siyeon Park, Seongyeol Park, Tae Min Kim, Soyeon Kim, Jaemoon Koh, Joonoh Lim, Kijong Yi, Boram Yi, Young Seok Ju, Miso Kim, Bhumsuk Keam, Jung Sun Kim, Yoon Kyung Jeon, Dong-Wan Kim, Young Tae Kim, Dae Seog Heo

Source: Biagio Ricciuti/X

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.